This phase II trial studies the side effects and how well nivolumab and trametinib with or
without dabrafenib work in treating patients with BRAF-mutated or wild type stage III-IV
melanoma that has spread to other places in the body or cannot be removed by surgery.
Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in the body's
immune system and may interfere with the ability of tumor cells to grow and spread.
Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. It is not yet known if nivolumab and trametinib with or without
dabrafenib may work better in treating patients with BRAF-mutated or wild type metastatic